Marshall Wace LLP Sells 204,107 Shares of Inogen, Inc. (NASDAQ:INGN)

Marshall Wace LLP lessened its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 62.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,205 shares of the medical technology company's stock after selling 204,107 shares during the period. Marshall Wace LLP owned approximately 0.53% of Inogen worth $1,018,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. acquired a new position in shares of Inogen in the second quarter valued at about $30,000. PNC Financial Services Group Inc. raised its holdings in Inogen by 2,918.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 7,646 shares in the last quarter. CWM LLC lifted its position in shares of Inogen by 2,185.9% during the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company's stock valued at $54,000 after acquiring an additional 6,339 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Inogen during the 1st quarter worth $81,000. Finally, Pitcairn Co. bought a new position in shares of Inogen in the first quarter worth $86,000. Institutional investors and hedge funds own 89.94% of the company's stock.

Inogen Stock Up 0.3 %

Shares of INGN stock traded up $0.03 during mid-day trading on Tuesday, reaching $9.19. 279,668 shares of the stock traded hands, compared to its average volume of 352,933. The company has a market cap of $216.67 million, a price-to-earnings ratio of -2.21 and a beta of 1.04. The stock's fifty day simple moving average is $11.02 and its two-hundred day simple moving average is $9.09. Inogen, Inc. has a 1-year low of $4.13 and a 1-year high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.31. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The business had revenue of $88.77 million during the quarter, compared to the consensus estimate of $82.50 million. During the same period in the prior year, the business posted ($0.42) earnings per share. Inogen's quarterly revenue was up 6.1% on a year-over-year basis. On average, equities research analysts anticipate that Inogen, Inc. will post -1.92 EPS for the current fiscal year.

Analysts Set New Price Targets

INGN has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research note on Wednesday, August 7th. StockNews.com raised Inogen from a "sell" rating to a "hold" rating in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.